Patrick Campbell

Jonathan Silverberg, MD, PhD, MPH, discusses how the results of the LEVEL UP trial impact treatment decisions for patients with moderate-to-severe atopic dermatitis.

LEVEL UP data presented at RAD 2024 provide additional insight into the phase 3b/4 trial comparing upadacitinib and dupilumab in atopic dermatitis beyond the primary endpoint.

Study from RAD 2024 finds 36% higher risk of nonmelanoma skin cancer in patients with atopic dermatitis relative to matched controls.

An analysis of data from the LIBERTY AD trial presented at RAD 2024 details the risk of infections observed with dupilumab use with up to 5 years of follow-up.

An analysis of data from the NIH's All of Us program details the prevalence of fatigue among patients with pruritus among US patients.

A real-world analysis of 60 patients suggests traolkinumab was effective in atopic dermatitis, regardless of prior therapy use.

At Heart in Diabetes, full results of the GRACE trial detailed the benefits of relacorilant use from both parts of the 2-part, phase 3 trial.

Kaitlin Mayne, MBChB, discusses an analysis of the EMPA-Kidney trial examining the effects of multimorbidity, polypharmacy, and quality of life on effects of empagliflozin.

A study found that only 0.32% of 1.2 million patients underwent Lp(a) testing, with non-Hispanic Black and Hispanic patients significantly less likely to receive the test compared to White patients.

Alexandra Louise Møller, MS, PhD, discusses the results of a PROVALID analysis examining the predictive value of endotrophin levels for predicting CKD events.

Mona Shahriari, MD, discusses how she foresees the role of nonsteroidal topical creams growing within the management of plaque psoriasis.

Mona Shahriari, MD, discusses the evolving role of nonsteroidal topical options the management of plaque psoriasis.

In our nephrology month in review for May 2024, we spotlight the biggest news from the NKF and ERA meetings, including the latest updates in IgA nephropathy, C3 glomerulopathy, chronic kidney disease, and more!

Our cardiology month in review spotlights the top 5 storylines that defined cardiology during May 2024, including new HCM guidelines, news from ESA 2024, and the FLOW trial.

Announced on May 29, 2024, data from the MDD3001 trial indicate use of seltorexant was associated with meaningful improvements in depressive symptoms and sleep disturbances.

Robert Rosenson, MD, discusses the results of the ARCHES-2 trial and how it informs the potential of ANGPTL3 inhibition as well as RNAi therapies.

Robert Rosenson, MD, discusses the unmet need in mixed hyperlipidemia and the potential for RNA interference therapies in this patient population.

A phase 2 trial suggests zodasiran significantly reduces triglycerides in patients with mixed hyperlipidemia, showing dose-dependent improvements in lipid profiles.

The FDA approved eculizumab-aeeb (Bkemv) as an interchangeable biosimilar to eculizumab (Soliris) for treating PNH and aHUS, marking the agency’s 53rd biosimilar approval.

Relacorilant achieves primary endpoint in phase 3 GRACE trial among patients with hypercortisolism and hyperglycemia, hypertension or both, with sNDA expected in Q3 2024.

Jonathan Barratt, MD, discusses a matching-adjusted indirect comparison of sparsentan and irbesartan against standard of care plus optimized RASI.

An analysis of more than 800 IgAN patients treated from 2002-2021 provides an overview of factors associated with anemia as well as its impact on prognosis.

Fadi Fakhouri, MD, PhD, discusses the 1-year results of the NOBLE trial examining use of pegcetacoplan in patients with post-transplant C3G or IC-MPGN.

A phase 2b dose-finding study suggests use of clazakizumab was associated with a reduction in hs-CRP among patients undergoing maintenance dialysis.

Jonathan Barratt, MD, discusses the 52-week data from the phase 1/2 trial of zigakibart, which was presented at the 61st European Renal Association Congress.

A Q&A with David Kavanagh, MBChB, PhD, on the results of the APPEAR-C3G trial and implications for care moving forward.

The phase 2 NOBLE trial shows pegcetacoplan reduces disease activity in post-transplant C3G and IC-MPGN, with benefits persisting through the 40-week double-blind period.

In the APPEAR-C3G trial, iptacopan reduced proteinuria by 35.1% in patients with C3 glomerulopathy, with Novartis planning regulatory submissions for C3G before the end of 2024.

Helen Colhoun, MD, discusses the results of a SELECT analysis she presented at the 61st European Renal Association Congress.

Semaglutide 2.4 mg reduces kidney events in SELECT participants, showing renoprotective effects in addition to cardiovascular benefits.